Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 37 | 2024 | 322 | 5.520 |
Why?
|
| Brain Neoplasms | 37 | 2024 | 587 | 4.510 |
Why?
|
| Deep Brain Stimulation | 14 | 2023 | 49 | 2.830 |
Why?
|
| Parkinson Disease | 6 | 2024 | 68 | 1.400 |
Why?
|
| Meningioma | 6 | 2022 | 51 | 1.360 |
Why?
|
| Meningeal Neoplasms | 6 | 2022 | 46 | 1.330 |
Why?
|
| Alzheimer Disease | 6 | 2014 | 312 | 1.280 |
Why?
|
| Radiation Injuries | 3 | 2023 | 67 | 1.110 |
Why?
|
| Retrospective Studies | 36 | 2024 | 3111 | 1.090 |
Why?
|
| Treatment Outcome | 32 | 2023 | 3099 | 1.040 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2020 | 337 | 0.980 |
Why?
|
| Humans | 77 | 2024 | 29093 | 0.920 |
Why?
|
| Trigeminal Neuralgia | 3 | 2019 | 33 | 0.830 |
Why?
|
| Middle Aged | 48 | 2020 | 10829 | 0.800 |
Why?
|
| Fornix, Brain | 4 | 2014 | 7 | 0.800 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 68 | 0.760 |
Why?
|
| Brain | 6 | 2023 | 930 | 0.750 |
Why?
|
| Neurons | 2 | 2014 | 394 | 0.740 |
Why?
|
| Laser Therapy | 5 | 2023 | 52 | 0.720 |
Why?
|
| Salvage Therapy | 11 | 2020 | 118 | 0.720 |
Why?
|
| Glioblastoma | 5 | 2020 | 143 | 0.670 |
Why?
|
| Male | 50 | 2023 | 17807 | 0.670 |
Why?
|
| Female | 50 | 2023 | 18164 | 0.670 |
Why?
|
| Adult | 32 | 2020 | 8420 | 0.660 |
Why?
|
| Aged | 38 | 2023 | 9487 | 0.650 |
Why?
|
| Dopamine | 6 | 2024 | 226 | 0.600 |
Why?
|
| Emotions | 3 | 2024 | 48 | 0.570 |
Why?
|
| Gyrus Cinguli | 2 | 2013 | 22 | 0.560 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 84 | 0.560 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2023 | 8 | 0.560 |
Why?
|
| Depressive Disorder, Major | 2 | 2013 | 35 | 0.550 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2014 | 6 | 0.510 |
Why?
|
| Electric Stimulation Therapy | 1 | 2014 | 18 | 0.510 |
Why?
|
| Basal Ganglia | 1 | 2014 | 15 | 0.500 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 141 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 1218 | 0.490 |
Why?
|
| Memory | 2 | 2012 | 187 | 0.490 |
Why?
|
| Thalamus | 1 | 2014 | 39 | 0.480 |
Why?
|
| Neurosurgical Procedures | 4 | 2021 | 98 | 0.480 |
Why?
|
| Corpus Striatum | 3 | 2020 | 60 | 0.470 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 3717 | 0.470 |
Why?
|
| Memory Disorders | 2 | 2010 | 61 | 0.460 |
Why?
|
| Hippocampus | 5 | 2018 | 185 | 0.450 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 2108 | 0.450 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 69 | 0.450 |
Why?
|
| Glioma | 3 | 2021 | 133 | 0.450 |
Why?
|
| Dementia | 1 | 2012 | 234 | 0.360 |
Why?
|
| Serotonin | 2 | 2020 | 35 | 0.350 |
Why?
|
| Disease-Free Survival | 7 | 2020 | 281 | 0.350 |
Why?
|
| Cognition Disorders | 1 | 2013 | 390 | 0.350 |
Why?
|
| Necrosis | 3 | 2023 | 53 | 0.340 |
Why?
|
| Neoplasms | 4 | 2020 | 610 | 0.330 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 384 | 0.330 |
Why?
|
| Electrodes, Implanted | 3 | 2022 | 41 | 0.320 |
Why?
|
| Decision Making | 2 | 2020 | 180 | 0.300 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 40 | 0.290 |
Why?
|
| Reward | 4 | 2024 | 63 | 0.280 |
Why?
|
| Syringomyelia | 1 | 2006 | 3 | 0.280 |
Why?
|
| Glioma, Subependymal | 1 | 2005 | 2 | 0.280 |
Why?
|
| Melanoma | 5 | 2019 | 148 | 0.280 |
Why?
|
| Spinal Injuries | 1 | 2006 | 20 | 0.280 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2005 | 5 | 0.280 |
Why?
|
| Prognosis | 9 | 2020 | 1362 | 0.270 |
Why?
|
| Nomograms | 3 | 2015 | 30 | 0.270 |
Why?
|
| Multiple Sclerosis | 2 | 2019 | 43 | 0.260 |
Why?
|
| Spinal Cord | 1 | 2006 | 139 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2024 | 109 | 0.250 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 20 | 0.250 |
Why?
|
| Punishment | 1 | 2023 | 2 | 0.240 |
Why?
|
| Kidney Neoplasms | 2 | 2024 | 192 | 0.230 |
Why?
|
| Voice Disorders | 1 | 2023 | 4 | 0.230 |
Why?
|
| Essential Tremor | 1 | 2023 | 13 | 0.230 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 88 | 0.220 |
Why?
|
| Postoperative Complications | 3 | 2018 | 670 | 0.220 |
Why?
|
| Epilepsy | 1 | 2023 | 59 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 30 | 0.220 |
Why?
|
| Young Adult | 10 | 2020 | 2402 | 0.220 |
Why?
|
| Cohort Studies | 5 | 2019 | 1687 | 0.210 |
Why?
|
| Alcoholism | 1 | 2023 | 95 | 0.210 |
Why?
|
| Hypothalamus | 2 | 2012 | 18 | 0.210 |
Why?
|
| Combined Modality Therapy | 6 | 2022 | 525 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 93 | 0.200 |
Why?
|
| Brain Edema | 2 | 2014 | 16 | 0.200 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 117 | 0.190 |
Why?
|
| Radiotherapy | 2 | 2018 | 74 | 0.190 |
Why?
|
| Sulfones | 1 | 2020 | 14 | 0.190 |
Why?
|
| Genomics | 2 | 2018 | 82 | 0.190 |
Why?
|
| Indans | 1 | 2020 | 25 | 0.190 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 39 | 0.190 |
Why?
|
| Time Factors | 5 | 2017 | 2001 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 199 | 0.180 |
Why?
|
| Carcinoma | 1 | 2020 | 87 | 0.180 |
Why?
|
| Visual Perception | 1 | 2020 | 112 | 0.180 |
Why?
|
| Survival Rate | 5 | 2020 | 795 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2020 | 440 | 0.170 |
Why?
|
| Adolescent | 8 | 2020 | 3254 | 0.170 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 88 | 0.160 |
Why?
|
| Astrocytoma | 1 | 2018 | 30 | 0.160 |
Why?
|
| Feedback, Psychological | 1 | 2018 | 5 | 0.160 |
Why?
|
| Mental Recall | 1 | 2018 | 52 | 0.160 |
Why?
|
| Recurrence | 2 | 2015 | 235 | 0.160 |
Why?
|
| Disease Progression | 4 | 2018 | 572 | 0.160 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 59 | 0.160 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 97 | 0.150 |
Why?
|
| Tremor | 2 | 2023 | 11 | 0.150 |
Why?
|
| Medicare | 1 | 2018 | 186 | 0.150 |
Why?
|
| Nervous System Neoplasms | 1 | 2017 | 8 | 0.150 |
Why?
|
| Seizures | 3 | 2023 | 61 | 0.150 |
Why?
|
| Signal Transduction | 1 | 2020 | 666 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 32 | 0.150 |
Why?
|
| Temporal Lobe | 1 | 2016 | 41 | 0.140 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 666 | 0.140 |
Why?
|
| Hypesthesia | 1 | 2015 | 10 | 0.140 |
Why?
|
| Treatment Failure | 4 | 2020 | 159 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 179 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 546 | 0.130 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 11 | 0.130 |
Why?
|
| Neurofibromatosis 2 | 1 | 2015 | 5 | 0.130 |
Why?
|
| Hyperthermia, Induced | 2 | 2016 | 235 | 0.130 |
Why?
|
| Carmustine | 1 | 2015 | 8 | 0.130 |
Why?
|
| Atrophy | 1 | 2014 | 51 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2015 | 83 | 0.130 |
Why?
|
| Reoperation | 1 | 2015 | 203 | 0.130 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 6 | 0.130 |
Why?
|
| Levodopa | 1 | 2014 | 14 | 0.120 |
Why?
|
| Incidence | 4 | 2020 | 1119 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 301 | 0.120 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.120 |
Why?
|
| Ecchymosis | 1 | 2013 | 2 | 0.120 |
Why?
|
| Skull Base | 1 | 2013 | 3 | 0.120 |
Why?
|
| Orbital Diseases | 1 | 2013 | 7 | 0.120 |
Why?
|
| Skull Fractures | 1 | 2013 | 17 | 0.120 |
Why?
|
| Smoking | 1 | 2017 | 427 | 0.120 |
Why?
|
| Neural Pathways | 2 | 2010 | 97 | 0.120 |
Why?
|
| Models, Neurological | 1 | 2014 | 115 | 0.120 |
Why?
|
| Brain Mapping | 2 | 2012 | 182 | 0.120 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.120 |
Why?
|
| Pain | 1 | 2015 | 282 | 0.110 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.110 |
Why?
|
| Affect | 1 | 2013 | 63 | 0.110 |
Why?
|
| Craniocerebral Trauma | 1 | 2013 | 56 | 0.110 |
Why?
|
| Subthalamic Nucleus | 1 | 2012 | 14 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.110 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 379 | 0.110 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.110 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2012 | 1 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2024 | 69 | 0.110 |
Why?
|
| Pain Measurement | 1 | 2014 | 364 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 709 | 0.110 |
Why?
|
| Craniotomy | 2 | 2017 | 44 | 0.110 |
Why?
|
| Radiotherapy Dosage | 3 | 2017 | 98 | 0.100 |
Why?
|
| Child | 4 | 2020 | 2219 | 0.100 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2010 | 2 | 0.100 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2010 | 1 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 92 | 0.100 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 29 | 0.100 |
Why?
|
| Frontal Lobe | 1 | 2010 | 45 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2010 | 71 | 0.090 |
Why?
|
| Radiation Dosage | 2 | 2020 | 72 | 0.090 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 172 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2019 | 2019 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 3531 | 0.080 |
Why?
|
| Ablation Techniques | 2 | 2018 | 24 | 0.080 |
Why?
|
| Amygdala | 2 | 2019 | 60 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2020 | 332 | 0.080 |
Why?
|
| Pedunculopontine Tegmental Nucleus | 1 | 2007 | 1 | 0.080 |
Why?
|
| Movement Disorders | 1 | 2007 | 25 | 0.070 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2005 | 4 | 0.070 |
Why?
|
| Stereotaxic Techniques | 2 | 2016 | 23 | 0.070 |
Why?
|
| Headache | 1 | 2005 | 74 | 0.070 |
Why?
|
| Quality of Life | 2 | 2023 | 816 | 0.070 |
Why?
|
| Animals | 4 | 2023 | 7297 | 0.060 |
Why?
|
| Mammals | 1 | 2023 | 9 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2015 | 130 | 0.060 |
Why?
|
| Lasers | 1 | 2023 | 19 | 0.060 |
Why?
|
| Motivation | 1 | 2024 | 102 | 0.060 |
Why?
|
| Learning | 1 | 2023 | 76 | 0.060 |
Why?
|
| Immersion | 1 | 2022 | 3 | 0.060 |
Why?
|
| Gelatin | 1 | 2022 | 27 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2022 | 26 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 637 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 45 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 69 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 68 | 0.050 |
Why?
|
| Hydrogels | 1 | 2022 | 103 | 0.050 |
Why?
|
| Collagen | 1 | 2022 | 217 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 145 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 113 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2020 | 155 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2020 | 276 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 161 | 0.040 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2022 | 386 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 289 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 10 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 680 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 573 | 0.040 |
Why?
|
| Avoidance Learning | 1 | 2018 | 18 | 0.040 |
Why?
|
| Neuronavigation | 1 | 2017 | 8 | 0.040 |
Why?
|
| Hearing Tests | 1 | 2017 | 11 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2022 | 608 | 0.040 |
Why?
|
| Brain Death | 1 | 2017 | 27 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2016 | 9 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2017 | 56 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2016 | 48 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2017 | 140 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2016 | 68 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2020 | 1167 | 0.040 |
Why?
|
| Retreatment | 1 | 2016 | 40 | 0.040 |
Why?
|
| Disease Management | 1 | 2017 | 114 | 0.040 |
Why?
|
| Biopsy | 1 | 2017 | 241 | 0.040 |
Why?
|
| Games, Experimental | 1 | 2015 | 4 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 454 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 16 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 76 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 72 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 60 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 2368 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 220 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 196 | 0.030 |
Why?
|
| Facial Pain | 1 | 2014 | 21 | 0.030 |
Why?
|
| Canada | 1 | 2013 | 48 | 0.030 |
Why?
|
| Glucose | 1 | 2014 | 163 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 859 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 159 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 23 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 174 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 896 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 1423 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2010 | 84 | 0.020 |
Why?
|
| United States | 1 | 2018 | 3630 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 430 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 871 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 526 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 747 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1604 | 0.020 |
Why?
|